This activity is for healthcare professionals outside of the UK.

This activity is provided by an independent medical education grant from Revolution Medicines.

The activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

Faculty & Disclosures

Listen on the go

    • View and download resources from this activity to support your learning and share with colleagues.

    Download Slides
    Download Practice Aid
    CORRECT!
    Next question
    Faculty & Disclosures
    Dr David S Hong

    The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Dr David S Hong, MD, is a medical oncologist specializing in early-phase clinical trials and the development of targeted therapies for solid tumours. He serves as deputy chair and professor of investigational cancer therapeutics at The University of Texas MD Anderson Cancer Center. read more

    Dr Hong has been instrumental in advancing treatments targeting RAS mutations, particularly in solid tumours. His research has significantly contributed to the development of KRAS G12C inhibitors, such as sotorasib, demonstrating their efficacy in patients with advanced solid tumours harbouring this mutation. 

    In addition to his work on KRAS G12C, Dr Hong has led studies on novel inhibitors targeting other RAS mutations. Dr Hong’s dedication to translational research and personalized medicine has been pivotal in bringing innovative RAS-targeted therapies from the laboratory to clinical application, offering new hope for patients with previously untreatable RAS-mutant cancers.

    Dr David S Hong discloses: Consultant, speaker, advisory board or panel fees from 280Bio, AbbVie, Acuta, Adaptimmune, Affini-T, Alkermes, Alpha Insights, Amgen, Astellas, Aumbiosciences, Axiom, Baxter, Bayer, Blackstone, Boxer Capital, BridgeBio, CARSgen, CLCC, COG, Cowen, CrossBridge Bio, Ecor1, EDDC, Erasca, Exelixis, F Hoffmann-La Roche, Fate Therapeutics, Genentech, Gennao Bio, Gilead, GLG, Group H, Guidepoint, HCW Precision Oncology, Immunogenesis, Incyte Inc, InduPro, Inhibrix Inc, Innovent, Janssen, Jounce Therapeutics Inc, Lan-Bio, Liberium, MedaCorp, MolecularMatch, Novartis, Numab, Oncologia Brasil, OncoResponse, ORI Capital, Pfizer, Pharma Intelligence, Prime Oncology, Quanta, RAIN, Revolution Medicines, Ridgeline, SeaGen, STCube, T-Knife, Takeda, Tavistock, Telperian, Trieza Therapeutics, Turning Point Therapeutics, YingLing Pharma and Ziopharm. Grants/research support from 280Bio, AbbVie, Adaptimmune, Adlai-Nortye, Amgen, Astelles, AstraZeneca, Bayer, Biomea, Bristol Myers Squibb, Daiichi Sankyo, Deciphera, Eisai, Eli Lilly, Endeavor, Erasca, F Hoffmann-LaRoche, Fate Therapeutics, Genentech, Genmab, Immunogenesis, Infinity, Inhibrix Inc, Mirati, Navier, Novartis, Numab, Pfizer, Pyramid Bio, Quanta, Revolution Medicines, SeaGen, STCube, Takeda, TCR2, Turning Point Therapeutics and VM Oncology. Travel, accomodation and/or expense reimbursement from Bayer, CLCC, Genmab, SITC and Telperian.
    Dr Eileen M O’Reilly

    Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA

    Dr Eileen M O’Reilly, MD, FASCO, holds the Winthrop Rockefeller Endowed Chair in Medical Oncology at Memorial Sloan Kettering (MSK). She serves as the section head for hepatopancreaticobiliary/neuroendocrine cancers, gastrointestinal oncology service; co-director for medical initiatives at the David M Rubenstein Center for Pancreatic Cancer; is an attending physician and member at MSK; and professor of medicine at Weill Cornell Medical College. read more

    Dr O’Reilly received her medical degree at Trinity College in Ireland. She completed her postgraduate training in Ireland and subsequent haematology/oncology fellowship training at MSK. Dr O’Reilly is a clinical scientist whose research focus involves integration of molecular and genetic-based therapies for pancreatic cancer along with development of adjuvant and neoadjuvant treatments and identification of biomarkers for therapy selection. Dr O’Reilly teaches and mentors junior faculty, oncology fellows, residents and medical/other students and has numerous teaching and other awards. Dr O’Reilly is the principal investigator (PI) of multiple phase I, II, III trials in pancreatic cancer and has authored/co-authored ~400 articles, editorials, and book chapters and has an H-index of 93. She serves as an associate editor for the Journal of Clinical Oncology and senior editor for several other journals, and has served on multiple grant review panels including, for the American Society of Clinical Oncology (ASCO), American Association of Cancer Research (AACR), NIH, DOD, and various international entities. She is PI of the MSK Pancreas Specialized Program in Oncology Research Excellence (SPORE), an NCI funded team science grant. Dr O’Reilly is the recipient of numerous awards including the Burkitt Medal (TCD) in 2022, and Giants of Cancer Care GI Oncology, 2023. 

    Dr O’Reilly’s other responsibilities include chair of the Human Research Protection Program and Institutional Review & Privacy Board (IRB). Nationally, Dr O’Reilly is co-chair of the NCI Alliance Co-Operative Group Gastrointestinal Cancers Committee and serves on the NCI Gastrointestinal Cancers Steering Committee (GISC) and serves in leadership roles in several advocacy organizations including National Pancreas Foundation, Hirshberg Foundation and Pancreas Cancer Action Network.

    Dr Eileen M O’Reilly discloses: Advisory board or panel fees from Ability Pharma, Agenus, Alligator BioSciences, Arcus, Astellas, AstraZeneca, BioNTech, BMS, Fibrogen, Ipsen, Leap Therapeutics, Merck, Merus, Moma Therapeutics, Novartis, Regeneron, Revolution Medicines, Syros and Tango. Grants/research support (all to institution) from Agenus, Amgen, Arcus, AstraZeneca, BioNTech, Digestive Care, Elicio, Genentech/Roche, Parker Institute and Revolution Medicines. Other financial or material support (royalties, patent, etc.) from Imedex and Stand Up To Cancer.
    Dr Rebecca S Heist

    Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    Dr Rebecca S Heist, MD, is a thoracic oncologist at the Massachusetts General Hospital (MGH) Cancer Center, with research interests in clinical trials of novel investigational agents in lung cancer and molecular targets in cancer. She is an active member of both the Thoracic Oncology group and the Termeer Center for Targeted Therapeutics at MGH, leading first-in-human clinical trials of investigational drugs.

    Dr Rebecca S Heist discloses: Consultancy fees from Amgen, AstraZeneca, Biohaven, Claim, Daiichi Sankyo, Gilead, Lilly, Merck, Novartis and Regeneron. Grants/research support (all to institution) from AstraZeneca, Daiichi Sankyo, Erasca, Lilly, Mirati, Mythic, Novartis and Turning Point.
    Back to Faculty
    touchONCOLOGY touchONCOLOGY
    SEE ALL VIDEOS
    Start activity

    Tutorial

    This icon indicates there is a poll question. Click it when you see it to interact with your peers.

    Poll

    When do you currently test for RAS mutations?

    Submit your answer to see the results

    At diagnosis
       
    After progression on first-line therapy
       
    After progression on second-line therapy
       
    I don’t routinely test for RAS mutations
       

    Tutorial

    This icon indicates there is a poll question. Click it when you see it to interact with your peers.

    Poll

    How do you currently incorporate RAS-targeted therapies in practice?

    Submit your answer to see the results

    Routinely for eligible patients
       
    Occasionally, based on specific patient factors
       
    Rarely, due to lack of access to or confidence in data
       
    Not at all, waiting for more robust clinical evidence
       

    Tutorial

    This icon indicates there is a poll question. Click it when you see it to interact with your peers.

    Poll

    How often do RAS mutations influence your treatment decisions?

    Submit your answer to see the results

    Often
       
    Sometimes
       
    Rarely
       
    Never
       
    Not sure
       
     
    Expert Interviews
    Lung Cancer, Pancreatic Cancer CE/CME accredited

    touchEXPERT OPINIONS
    Experts answer questions with in-depth advice on the current clinical landscape and how new therapies and guidance might impact regional clinical practice. Useful tips below will show how to navigate the activity. Close

    RAS mutations and personalized cancer care: Targeting the future

    Take CE/CME Test

    Dr David S Hong, MD, is a medical oncologist specializing in early-phase clinical trials and the development of targeted therapies for solid tumours. He serves as deputy chair and professor of investigational cancer therapeutics at The University of Texas MD Anderson Cancer Center. read more

    Dr Hong has been instrumental in advancing treatments targeting RAS mutations, particularly in solid tumours. His research has significantly contributed to the development of KRAS G12C inhibitors, such as sotorasib, demonstrating their efficacy in patients with advanced solid tumours harbouring this mutation. 

    In addition to his work on KRAS G12C, Dr Hong has led studies on novel inhibitors targeting other RAS mutations. Dr Hong’s dedication to translational research and personalized medicine has been pivotal in bringing innovative RAS-targeted therapies from the laboratory to clinical application, offering new hope for patients with previously untreatable RAS-mutant cancers.

    Dr David S Hong discloses: Consultant, speaker, advisory board or panel fees from 280Bio, AbbVie, Acuta, Adaptimmune, Affini-T, Alkermes, Alpha Insights, Amgen, Astellas, Aumbiosciences, Axiom, Baxter, Bayer, Blackstone, Boxer Capital, BridgeBio, CARSgen, CLCC, COG, Cowen, Ecor1, EDDC, Erasca, Exelixis, F Hoffmann-La Roche, Fate Therapeutics, Genentech, Gennao Bio, Gilead, GLG, Group H, Guidepoint, HCW Precision Oncology, Immunogenesis, Incyte Inc, InduPro, Inhibrix Inc, Innovent, Janssen, Jounce Therapeutics Inc, Lan-Bio, Liberium, MedaCorp, Novartis, Numab, Oncologia Brasil, ORI Capital, Pfizer, Pharma Intelligence, Prime Oncology, Quanta, RAIN, Revolution Medicines, Ridgeline, SeaGen, STCube, T-Knife, Takeda, Tavistock, Trieza Therapeutics, Turning Point Therapeutics, YingLing Pharma and Ziopharm. Grants/research support from 280Bio, AbbVie, Adaptimmune, Adlai-Nortye, Amgen, Astelles, AstraZeneca, Bayer, Biomea, Bristol Myers Squibb, Daiichi Sankyo, Deciphera, Eisai, Eli Lilly, Endeavor, Erasca, F Hoffmann-LaRoche, Fate Therapeutics, Genentech, Genmab, Immunogenesis, Infinity, Inhibrix Inc, Mirati, Navier, Novartis, Numab, Pfizer, Pyramid Bio, Quanta, Revolution Medicines, SeaGen, STCube, Takeda, TCR2, Turning Point Therapeutics and VM Oncology. Travel, accomodation and/or expense reimbursement from Bayer, CLCC, Genmab, SITC and Telperian.

    Take CE/CME Test

    Dr Eileen M O’Reilly, MD, FASCO, holds the Winthrop Rockefeller Endowed Chair in Medical Oncology at Memorial Sloan Kettering (MSK). She serves as the section head for hepatopancreaticobiliary/neuroendocrine cancers, gastrointestinal oncology service; co-director for medical initiatives at the David M Rubenstein Center for Pancreatic Cancer; is an attending physician and member at MSK; and professor of medicine at Weill Cornell Medical College. read more

    Dr O’Reilly received her medical degree at Trinity College in Ireland. She completed her postgraduate training in Ireland and subsequent haematology/oncology fellowship training at MSK. Dr O’Reilly is a clinical scientist whose research focus involves integration of molecular and genetic-based therapies for pancreatic cancer along with development of adjuvant and neoadjuvant treatments and identification of biomarkers for therapy selection. Dr O’Reilly teaches and mentors junior faculty, oncology fellows, residents and medical/other students and has numerous teaching and other awards. Dr O’Reilly is the principal investigator (PI) of multiple phase I, II, III trials in pancreatic cancer and has authored/co-authored ~400 articles, editorials, and book chapters and has an H-index of 93. She serves as an associate editor for the Journal of Clinical Oncology and senior editor for several other journals, and has served on multiple grant review panels including, for the American Society of Clinical Oncology (ASCO), American Association of Cancer Research (AACR), NIH, DOD, and various international entities. She is PI of the MSK Pancreas Specialized Program in Oncology Research Excellence (SPORE), an NCI funded team science grant. Dr O’Reilly is the recipient of numerous awards including the Burkitt Medal (TCD) in 2022, and Giants of Cancer Care GI Oncology, 2023. 

    Dr O’Reilly’s other responsibilities include chair of the Human Research Protection Program and Institutional Review & Privacy Board (IRB). Nationally, Dr O’Reilly is co-chair of the NCI Alliance Co-Operative Group Gastrointestinal Cancers Committee and serves on the NCI Gastrointestinal Cancers Steering Committee (GISC) and serves in leadership roles in several advocacy organizations including National Pancreas Foundation, Hirshberg Foundation and Pancreas Cancer Action Network.

    Dr Eileen M O’Reilly discloses: Advisory board or panel fees from Ability Pharma, Agenus, Alligator BioSciences, Arcus, Astellas, AstraZeneca, BioNTech, BMS, Fibrogen, Ipsen, Leap Therapeutics, Merck, Merus, Moma Therapeutics, Novartis, Regeneron, Revolution Medicines, Syros and Tango. Grants/research support (all to institution) from Agenus, Amgen, Arcus, AstraZeneca, BioNTech, Break Through Cancer, Digestive Care, Elicio, Genentech/Roche, NIH/NCI, Parker Institute and Revolution Medicines. Other financial or material support (royalties, patent, etc.) from American Association of Cancer Research, American Society of Clinical Oncology, Imedex, Research To Practice and Stand Up To Cancer.

    Take CE/CME Test

    Dr Rebecca S Heist, MD, is a thoracic oncologist at the Massachusetts General Hospital (MGH) Cancer Center, with research interests in clinical trials of novel investigational agents in lung cancer and molecular targets in cancer. She is an active member of both the Thoracic Oncology group and the Termeer Center for Targeted Therapeutics at MGH, leading first-in-human clinical trials of investigational drugs.

    Dr Rebecca S Heist discloses: Consultancy fees from Amgen, AstraZeneca, Biohaven, Claim, Daiichi Sankyo, Gilead, Lilly, Merck, Novartis and Regeneron. Grants/research support (all to institution) from AstraZeneca, Daiichi Sankyo, Erasca, Lilly, Mirati, Mythic, Novartis and Turning Point.

    Take CE/CME Test
    Podcast Featured
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Italian, Japanese, Spanish.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Describe the emergence and potential future clinical implications of RAS mutations as actionable targets for personalized care in solid tumours
    • Explain the significance of RAS mutations in the progression and treatment of NSCLC and pancreatic cancer
    • Evaluate the current and emerging clinical data on RAS-targeted therapies in the treatment of NSCLC and pancreatic cancer
    Overview

    In these short interviews, a medical oncologist, a pancreatic cancer specialist and a lung cancer specialist discuss the role of RAS mutations in solid tumours, notably pancreatic cancer and NSCLC, and how they may be therapeutically targeted to improve patient outcomes.

    This activity is jointly provided by USF Health and touchIME. read more

    Target Audience

    This activity has been designed to meet the educational needs of oncologists and pathologists involved in the management of pancreatic cancer and NSCLC.

    USF Accreditation

    Disclosures

    USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.

    Faculty

    Dr David S Hong discloses: Consultant, speaker, advisory board or panel fees from 280Bio, AbbVie, Acuta, Adaptimmune, Affini-T, Alkermes, Alpha Insights, Amgen, Astellas, Aumbiosciences, Axiom, Baxter, Bayer, Blackstone, Boxer Capital, BridgeBio, CARSgen, CLCC, COG, Cowen, CrossBridge Bio, Ecor1, EDDC, Erasca, Exelixis, F Hoffmann-La Roche, Fate Therapeutics, Genentech, Gennao Bio, Gilead, GLG, Group H, Guidepoint, HCW Precision Oncology, Immunogenesis, Incyte Inc, InduPro, Inhibrix Inc, Innovent, Janssen, Jounce Therapeutics Inc, Lan-Bio, Liberium, MedaCorp, MolecularMatch, Novartis, Numab, Oncologia Brasil, OncoResponse, ORI Capital, Pfizer, Pharma Intelligence, Prime Oncology, Quanta, RAIN, Revolution Medicines, Ridgeline, SeaGen, STCube, T-Knife, Takeda, Tavistock, Telperian, Trieza Therapeutics, Turning Point Therapeutics, YingLing Pharma and Ziopharm. Grants/research support from 280Bio, AbbVie, Adaptimmune, Adlai-Nortye, Amgen, Astelles, AstraZeneca, Bayer, Biomea, Bristol Myers Squibb, Daiichi Sankyo, Deciphera, Eisai, Eli Lilly, Endeavor, Erasca, F Hoffmann-LaRoche, Fate Therapeutics, Genentech, Genmab, Immunogenesis, Infinity, Inhibrix Inc, Mirati, Navier, Novartis, Numab, Pfizer, Pyramid Bio, Quanta, Revolution Medicines, SeaGen, STCube, Takeda, TCR2, Turning Point Therapeutics and VM Oncology. Travel, accomodation and/or expense reimbursement from Bayer, CLCC, Genmab, SITC and Telperian.

    Dr Eileen M O’Reilly discloses: Advisory board or panel fees from Ability Pharma, Agenus, Alligator BioSciences, Arcus, Astellas, AstraZeneca, BioNTech, BMS, Fibrogen, Ipsen, Leap Therapeutics, Merck, Merus, Moma Therapeutics, Novartis, Regeneron, Revolution Medicines, Syros and Tango. Grants/research support (all to institution) from Agenus, Amgen, Arcus, AstraZeneca, BioNTech, Digestive Care, Elicio, Genentech/Roche, Parker Institute and Revolution Medicines. Other financial or material support (royalties, patent, etc.) from Imedex and Stand Up To Cancer.

    Dr Rebecca S Heist discloses: Consultancy fees from Amgen, AstraZeneca, Biohaven, Claim, Daiichi Sankyo, Gilead, Lilly, Merck, Novartis and Regeneron. Grants/research support (all to institution) from AstraZeneca, Daiichi Sankyo, Erasca, Lilly, Mirati, Mythic, Novartis and Turning Point.

    Content reviewer

    Danielle Walker, DNP, APRN, AGNP-C has no relevant financial relationships to disclose.

    Touch Medical Contributors

    Annette Wiggins/Christina Mackins-Crabtree has no financial interests/relationships or affiliations in relation to this activity.

    USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

    Requirements for Successful Completion

    In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

    If you have questions regarding credit please contact cpdsupport@usf.edu 

    Accreditations

    Physicians

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

    USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Advanced Practice Providers

    Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

    The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

    Date of original release: 30 January 2025. Date credits expire: 30 January 2028.

    If you have any questions regarding credit, please contact cpdsupport@usf.edu

    EBAC® Accreditation

    touchIME is an EBAC® accredited provider since 2023.

    This programme is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 0.75 hour of effective education time.

    EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.

    Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

    EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).

    Faculty Disclosure Statement / Conflict of Interest Policy

    In compliance with EBAC® guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event have been mitigated and declared to the audience prior to the CME activities.

    Requirements for Successful Completion

    Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBAC® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBAC® CE credit certificate. EBAC® grants 1 CE credit for every hour of education completed.

    Date of original release: 30 January 2025. Date credits expire: 30 January 2027.

    Time to Complete: 45 minutes

    If you have any questions regarding the EBAC® credits, please contact accreditation@touchime.org

     

    This activity is CE/CME accredited

    To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

    Claim Credit
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Italian, Japanese, Spanish.
    • A practice aid is available for this activity in the Toolkit
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    touchFOCUS

    Overcoming challenges in advanced or metastatic squamous cell lung cancer: Focus on immunotherapy

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Gerard Zalcman, ESMO 2022: IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab in advanced non-small cell lung cancer

    GO TO HUB

    CONFERENCE HUB

    Lizza Hendriks, ELCC 2022: Immunotherapy for Non-oncogene Addicted NSCLC With Brain Metastases

    GO TO HUB

    touchPANEL DISCUSSION

    Targeting IL-1β in NSCLC: What does the future hold?

    LAUNCH ACTIVITY

    JOURNALS

    American Society of Clinical Oncology 2015— Highlights of Non-colorectal Gastrointestinal Cancers

    GO TO ARTICLE

    JOURNALS

    Developments in the Treatment of Pancreatic Cancer

    GO TO ARTICLE

    Topics covered in this activity

    Lung Cancer / Pancreatic Cancer
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 100+ hours of bite-sized congress highlights
    • 10 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now
    This Activity Is Funded By:

    An independent medical education grant from Revolution Medicines.

    The activity is jointly provided by USF Health and touchIME.

    touchIME is an EBAC® accredited provider.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgement of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    Date of original release: 30 January 2025. Date credits expire: 30 January 2028.

    EBAC® 

    touchIME is an EBAC® accredited provider since 2023.

    In compliance with EBAC® guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals.

    Claim Credit
    touchEXPERT OPINIONS
    RAS mutations and personalized cancer care: Targeting the future
    0.75 CE/CME credit
    Question 1/5
    Which of the following strategies could represent a future direction in targeting RAS mutations in solid tumours?

    The ongoing unmet need for RAS targeting cannot be completely achieved with available KRAS G12C inhibitors. It is essential to extend treatment options to tumours bearing KRAS non-G12C mutations, which account for the majority of PDAC, CRC and NSCLC cases. In order to overcome this unmet need, RAS(ON) multi-selective, or pan-RAS, inhibitors have recently been introduced. These first RAS(ON) multi-selective tri-complex inhibitor studies are expected to set the basis for future clinical research and could potentially facilitate the introduction of RAS(ON) multi-selective tri-complex inhibitors into standard oncology care.  

    Abbreviations

    CRC, colorectal cancer; NSCLC, non-small cell lung cancer; PDAC, pancreatic ductal adenocarcinoma.

    Reference

    Filis P, et al. Drug Discov Today. 2024;30:104250.

    Question 2/5
    Which of the following is a key limitation to ctDNA testing in pancreatic cancer?

    ctDNA, circulating tumour DNA.

    Recently, ctDNA has gained attention for its role in identifying KRAS mutations, which is relevant for assessing tumour dynamics and response to treatment. ctDNA has been used to track mutations in KRAS, which is common in pancreatic cancer and can contribute to its aggressive nature. One of the key limitations for using ctDNA testing in patients with pancreatic cancer is the fact that it is limited by tumour shedding rates.

    Abbreviation

    ctDNA, circulating tumour DNA.

    Reference

    Yu B, et al. Cancer Lett. 2025;610:217350.

    Question 3/5
    You have a 65 year-old patient with advanced pancreatic cancer whose disease has progressed following surgery and adjuvant chemotherapy. They have heard about a clinical trial investigating a novel KRAS-targeting therapy, RMC-9805. Which of the following factors will determine if they are a candidate for this study?

    NCT06040541 is an open-label, multicenter, phase I/Ib study of RMC-9805, a selective and orally bioavailable KRAS G12D inhibitor, in subjects with KRAS G12D-mutant solid tumours to evaluate the safety, tolerability, pharmacokinetics and preliminary clinical activity. The study consists of two arms: RMC-9805 monotherapy arm and RMC-9805 plus RMC-6236 combination arm. One of the main inclusion criteria for the trial is pathologically documented, locally advanced or metastatic solid tumour with a KRAS G12D mutation. 

    Reference

    ClinicalTrials.gov. NCT06040541. Available at: https://clinicaltrials.gov/study/NCT06040541 (accessed 9 December 2024).

    Question 4/5
    Your patient with advanced non-squamous NSCLC has progressed after chemotherapy. NGS testing shows KRAS G12C mutation. How should their treatment be personalized based on current evidence?

    EGFR, epidermal growth factor receptor; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1.

    Two targeted therapies are available as subsequent therapy options for NSCLC with KRAS G12C mutations. Adagrasib and sotorasib are oral small molecules that target KRAS G12C and have both been granted accelerated approval by the FDA for the treatment of adults with KRAS G12C-mutated locally advanced or metastatic NSCLC who received at least one prior systemic therapy.

    Abbreviation

    NSCLC, non-small cell lung cancer.

    Reference

    NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Version 2.2025. Available at: www.nccn.org/guidelines/ (accessed 9 January 2024).

    Question 5/5
    Based on NCCN guideline recommendations, when is the optimal time to test your patient with advanced non-squamous NSCLC for KRAS mutations?

    NCCN, National Comprehensive Cancer Network.

    As noted in the recently updated NCCN recommendations, molecular testing for EGFR, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, and ERBB2 (HER2) alterations is recommended in all patients with advanced or metastatic nonsquamous NSCLC (i.e. adenocarcinoma, large cell carcinoma) and NSCLC not otherwise specified.1 Currently, KRAS mutations are not actionable mutations in the first-line setting, as the KRAS G12C inhibitors sotorasib and adagrasib are only approved in the second-line setting and beyond.1 Nevertheless, as Lim et al. emphasize, “testing and reporting of the KRAS G12C variant should be included in routine biomarker testing prior to first-line therapy. KRAS G12C test results should be clearly documented in patients’ health records for actionability at progression.”2

    Abbreviations

    EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; NSCLC, non-small cell lung cancer.

    References

    1. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Version 2.2025. Available at: www.nccn.org/guidelines/ (accessed 9 January 2024).
    2. Lim TKH, et al. Lung Cancer. 2023;184:107293.
    Back to Activity

    You may also be interested in...

    touchPANEL DISCUSSION

    Expanding HER2 horizons: Implications for NSCLC and beyond

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Misako Nagasaka, ELCC 2022: Results of the TRUST-II Study

    GO TO HUB

    touchEXPERT OPINIONS

    Optimizing the management of gastroenteropancreatic neuroendocrine tumours

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Niels Reinmuth, ESMO 2019 – Phase III MYSTIC trial in NSCLC

    GO TO HUB

    JOURNALS

    Unmet Needs in the Treatment of Metastatic Non-small-cell Lung Cancer

    GO TO ARTICLE

    JOURNALS

    Advances in Pancreatic Cancer Treatment

    GO TO ARTICLE
    This Activity Is Funded By:

    An independent medical education grant from Revolution Medicines.

    The activity is jointly provided by USF Health and touchIME.

    touchIME is an EBAC® accredited provider.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgement of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    Date of original release: 30 January 2025. Date credits expire: 30 January 2028.

    EBAC® 

    touchIME is an EBAC® accredited provider since 2023.

    In compliance with EBAC® guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup